US4027005A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Diagnostic agents
Assignee: Bristol Myers Squibb Pharma Co
•
Filing: 1974-06-07
•
Granted: 1977-05-31
•
Expires: 1994-06-07
Abstract
Abstract Radionuclide diagnostic agents, comprising technetium-99m, a reducing agent, preferably a stannous reducing agent, and certain polyhydroxycarboxylic acids and derivatives thereof, i.e. glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid and salts thereof, are highly useful, both in the study and diagnosis of kidney morphology and function, and in the diagnosis of ischemic, infarcted or diseased tissue.
Inventors
- 👤 Norman Adler
- 👤 Leopoldo Lazaro Camin
- 👤 Paul Gold
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 22:51
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0491; A61K2123/00
Claims Analysis
Total Claims: 39
Claim 1
Independent Claim
34 words
A radioactive diagnostic composition, comprising a product of admixture of technetium-99m, a reducing agent, and salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 2
Dependent Claim
34 words
A radioactive diagnostic composition, comprising a product of admixture of technetium-99m, a reducing agent, and salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 3
Dependent Claim
14 words
The composition of claim 1, wherein said reducing agent comprises a stannous reducing agent.
Claim 4
Dependent Claim
24 words
The composition of claim 2, wherein the stannous reducing agent is present in an amount of at least 0.1 microgram per milliliter of composition.
Claim 5
Dependent Claim
26 words
The composition of claim 3, wherein the stannous reducing agent is present in an amount of from about 1 to 100 micrograms per milliliter of composition.
Claim 6
Dependent Claim
25 words
The composition of claim 3, wherein the stannous reducing agent is present in an amount of from 10 to 40 micrograms per milliliter of composition.
Claim 7
Dependent Claim
27 words
The composition of claim 3, wherein the stannous reducing agent is present in an amount of from 0.0005% to 0.5% by weight of the polyhydroxycarboxylic acid salt.
Claim 8
Dependent Claim
27 words
The composition of claim 3 wherein the stannous reducing agent is present in an amount of from 0.005% to 0.1% by weight of the polyhydroxycarboxylic acid salt.
Claim 9
Dependent Claim
21 words
The composition of claim 7, wherein the polyhydroxycarboxylic acid salt is an alkali or alkaline earth metal salt of glucoheptonic acid.
Claim 10
Dependent Claim
11 words
The composition of claim 7, further comprising a pharmacologically acceptable carrier.
Claim 11
Dependent Claim
38 words
A composition suitable for the preparation of a radioactive diagnostic agent, comprising a mixture of a reducing agent and salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 12
Dependent Claim
38 words
A composition suitable for the preparation of a radioactive diagnostic agent, comprising a mixture of a reducing agent and salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 13
Dependent Claim
14 words
The composition of claim 10, wherein said reducing agent is a stannous reducing agent.
Claim 14
Dependent Claim
26 words
The composition of claim 11, wherein said stannous reducing agent is present in amount of from 0.005% to 0.1% by weight of said polyhydroxycarboxylic acid salt.
Claim 15
Dependent Claim
11 words
The composition of claim 11, wherein said mixture is a solid.
Claim 16
Dependent Claim
35 words
A kit for forming a radioactive diagnostic composition comprising a reducing agent and a polyhydroxycarboxylic acid selected from the glucoheptonic acid lactobionic acid, galacturonic acid and glucuronic acid, packaged in a sealed, sterile, non-pyrogenic container.
Claim 17
Dependent Claim
35 words
A kit for forming a radioactive diagnostic composition comprising a reducing agent and a polyhydroxycarboxylic acid selected from the glucoheptonic acid lactobionic acid, galacturonic acid and glucuronic acid, packaged in a sealed, sterile, non-pyrogenic container.
Claim 18
Dependent Claim
13 words
The kit of claim 14, wherein said mixture is a freeze dried solid.
Claim 19
Dependent Claim
12 words
The kit of claim 15, wherein said polyhydroxycarboxylic acid comprises glucoheptonic acid.
Claim 20
Independent Claim
54 words
A method of concentrating 99m Tc in vivo in a kidney of a mammal comprising intravenously administering to the animal a radioactive composition comprising a product of admixture of technetium-99m, a reducing agent, and a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 21
Independent Claim
54 words
A method of concentrating 99m Tc in vivo in a kidney of a mammal comprising intravenously administering to the animal a radioactive composition comprising a product of admixture of technetium-99m, a reducing agent, and a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 22
Dependent Claim
30 words
The method of claim 17, wherein said composition contains sufficient technetium-99m to give radioactivity in the amount of from about 1 to 25 mCi per 75 kilograms of body weight.
Claim 23
Dependent Claim
30 words
The method of claim 17, wherein said composition contains sufficient technetium-99m to give radioactivity in the amount of from about 10 to 15 mCi per 75 kilograms of body weight.
Claim 24
Dependent Claim
30 words
The method of claim 17, wherein said reducing agent comprises a stannous reducing agent, and is present in an amount of at least 0.1 micrograms per milliliter of said mixture.
Claim 25
Dependent Claim
32 words
The method of claim 20, wherein said reducing agent is a stannous reducing agent, and is present in an amount of from about 0.0005 to 0.5% by weight of the polyhydroxycarboxylic acid.
Claim 26
Dependent Claim
12 words
The method of claim 21, wherein the polyhydroxycarboxylic acid is glucoheptonic acid.
Claim 27
Independent Claim
72 words
A method of concentrating technetium-99m in ischemic infarcted or diseased tissue in an animal comprising intravenously administering to the animal a radioactive composition comprising a product of admixture of technetium-99m, a stannous reducing agent, and a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, said stannous reducing agent being present in an amount of from 0.01 to 0.1% by weight of said polyhydroxycarboxylic acid.
Claim 28
Independent Claim
72 words
A method of concentrating technetium-99m in ischemic infarcted or diseased tissue in an animal comprising intravenously administering to the animal a radioactive composition comprising a product of admixture of technetium-99m, a stannous reducing agent, and a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, said stannous reducing agent being present in an amount of from 0.01 to 0.1% by weight of said polyhydroxycarboxylic acid.
Claim 29
Independent Claim
43 words
A method of preparing a radioactive diagnostic agent, comprising forming a mixture of a reducing agent and a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, and combining technetium-99m with said mixture.
Claim 30
Independent Claim
43 words
A method of preparing a radioactive diagnostic agent, comprising forming a mixture of a reducing agent and a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, and combining technetium-99m with said mixture.
Claim 31
Dependent Claim
16 words
The method of claim 24, wherein said mixture is lyophilized prior to being combined with technetium-99m.
Claim 32
Dependent Claim
102 words
A radioactive diagnostic composition, comprising a product of admixture of technetium-99m, a reducing agent selected from the group of stannous ions and ferrous ions, and a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, said reducing agent being present in an amount of from about 1 to 100 micrograms per milliliter of composition, the amount of said reducing agent being from about 0.0005 to 0.5% of said polyhydroxycarboxylic acid, and said technetium-99m being present in an amount sufficient to provide radioactivity in the amount of from about 1 to 25 mCi.
Claim 33
Dependent Claim
102 words
A radioactive diagnostic composition, comprising a product of admixture of technetium-99m, a reducing agent selected from the group of stannous ions and ferrous ions, and a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, said reducing agent being present in an amount of from about 1 to 100 micrograms per milliliter of composition, the amount of said reducing agent being from about 0.0005 to 0.5% of said polyhydroxycarboxylic acid, and said technetium-99m being present in an amount sufficient to provide radioactivity in the amount of from about 1 to 25 mCi.
Claim 34
Dependent Claim
28 words
A radioactive diagnostic composition comprising technetium-99m bound to a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 35
Dependent Claim
28 words
A radioactive diagnostic composition comprising technetium-99m bound to a salt of a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid.
Claim 36
Dependent Claim
21 words
The composition of claim 27, wherein the polyhydroxycarboxylic acid salt is an alkali or alkaline earth metal salt of glucoheptonic acid.
Claim 37
Independent Claim
45 words
A method of preparing a radioactive diagnostic agent, comprising forming a mixture of technetium-99m and a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, and subjecting said mixture to electrolysis in the presence of an oxidizable electrode.
Claim 38
Independent Claim
45 words
A method of preparing a radioactive diagnostic agent, comprising forming a mixture of technetium-99m and a polyhydroxycarboxylic acid selected from the group of glucoheptonic acid, lactobionic acid, galacturonic acid and glucuronic acid, and subjecting said mixture to electrolysis in the presence of an oxidizable electrode.
Claim 39
Dependent Claim
21 words
The method of claim 29, wherein the oxidizable electrode comprises a metal selected from the group of iron, tin and zirconium.
References Cited (Backward Citations)
US3725295A
Cited
US3749556A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-05-30 | 1980-11-29 | 1981-05-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-05-30 | 1984-11-29 | 1985-05-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-05-30 | 1988-11-29 | 1989-05-31 | $7700.00 | Window Closed / Lapsed |